Genzyme Corporation today announced that the FDA's Orthopaedic and Rehabilitation Devices Advisory Committee voted unanimously (5 - 0) in favor of approval without conditions of Synvisc-One TM (hylan ...
Please provide your email address to receive an email when new articles are posted on . The FDA Orthopaedic and Rehabilitation Devices Panel voted 5-0 Tuesday to recommend approving the premarket ...
CAMBRIDGE, Mass., Nov. 13 /PRNewswire-FirstCall/ -- Genzyme Corp. announced today that it has received a letter from the U.S. Food and Drug Administration requesting ...
Feb. 6, 2003 (New Orleans) — In a head-to-head study comparing intra-articular hylan GF-20 injection (Synvisc) to corticosteroid injection for knee osteoarthritis, "there was no difference in outcome ...
GAITHERSBURG, Maryland (Reuters) - A U.S. advisory panel has unanimously backed a new version of a Genzyme Corp injection to relieve knee pain from osteoarthritis. The panel of experts voted 5-0 on ...
Please provide your email address to receive an email when new articles are posted on . The FDA has granted marketing approval to Genzyme Corp. for its Synvisc-One product indicated for the relief of ...
Genzyme Corp. is challenging a decision by the Centers for Medicare and Medicaid Services to create a single reimbursement code for osteoarthritis treatments that would drop the reimbuirsement rate ...
4. Synvisc knee injections. There was a recent coding change in 2010 for synvisc knee injections with the J7325 code. “This code is to be used for synvisc injections regardless of whether the ...
(Recasts first paragraph; adds Genzyme comments, sales figures, competitors, byline; updates stock price) By Lisa Richwine GAITHERSBURG, Md., Dec 9 (Reuters) - A U.S. advisory panel has unanimously ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results